Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme

Cardiovascular Pathology

Volumn 17, Issue 6, 2008, Pages 399-409

  Zhang, Wei ^a,b   Zhong, Ming ^a,b   Yang, Gui rong ^a,b   Li, Jian ping ^a,b   Guo, Chenhong ^a,b   Wang, Zhihao ^a,b   Zhang, Yun ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b Qilu Hospital of Shandong University   (China)

Author keywords

Atrial fibrillation; Canine; Matrix metalloproteinase 9; Tissue inhibitors of metalloproteinase 1

Indexed keywords

ANGIOTENSIN II; CALCIUM ION; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM REMODELING; HEART LEFT ATRIUM; MALE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL FIBRILLATION; CALCIUM; CAPTOPRIL; DOGS; GENE EXPRESSION; HEART ATRIA; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 9; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 55249103828     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2008.02.008     Document Type: Article

References (30)

1. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
2. Wijffels M.C., Kirchhof C.J., Dorland R., and Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92 (1995) 1954-1968
3. Morillo C.A., Klein G.J., Jones D.L., and Guiraudon C.M. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91 (1995) 1588-1595
4. Tieleman R.G., Van Gelder I.C., Crijns H.J., De Kam P.J., Van Den Berg M.P., Haaksma J., et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria?. J Am Coll Cardiol 31 (1998) 167-173
5. Goette A., Honeycutt C., and Langberg J.J. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 94 (1996) 2968-2974
6. Everett IV T.H., Li H., Mangrum J.M., McRury I.D., Mitchell M.A., Redick J.A., et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 102 (2000) 1454-1460
7. Arndt M., Lendeckel U., Rocken C., Nepple K., Wolke C., Spiess A., et al. Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation 105 (2002) 720-725
8. Li Y.Y., Feldman A.M., Sun Y., and McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98 (1998) 1728-1734
9. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley III A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
10. Xu J., Cui G., Esmailian F., Plunkett M., Marelli D., Ardehali A., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
11. Ausma J., Wijffels M., Thone F., Wouters L., Allessie M., and Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96 (1997) 3157-3163
12. Shirani J., and Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol 9 (2000) 95-101
13. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104 (2001) 2608-2614
14. Boldt A., Scholl A., Garbade J., Resetar M.E., Mohr F.W., Gummert J.F., et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101 (2006) 261-267
15. Brundel B.J., Henning R.H., Kampinga H.H., Van Gelder I.C., and Crijns H.J. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 54 (2002) 315-324
16. Finkielstein D., and Schweitzer P. Role of angiotensin-converting enzyme inhibitors in the prevention of atrial fibrillation. Am J Cardiol 93 (2004) 734-736
17. Ducharme A., Swedberg K., Pfeffer M.A., Cohen-Solal A., Granger C.B., Maggioni A.P., et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 151 (2006) 985-991
18. Frangogiannis N.G., Mendoza L.H., Lindsey M.L., Ballantyne C.M., Michael L.H., Smith C.W., et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 165 (2000) 2798-2808
19. Kraan M.C., Smith M.D., Weedon H., Ahern M.J., Breedveld F.C., and Tak P.P. Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis 60 (2001) 296-298
20. Kostin S., Klein G., Szalay Z., Hein S., Bauer E.P., and Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54 (2002) 361-379
21. Kalifa J., Jalife J., Zaitsev A.V., Bagwe S., Warren M., Moreno J., et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108 (2003) 668-671
22. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97 (2000) 12746-12751
23. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 378 (1997) 151-160
24. Nakano Y., Niida S., Dote K., Takenaka S., Hirao H., Miura F., et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 43 (2004) 818-825
25. Brundel B.J., Ausma J., van Gelder I.C., Van der Want J.J., van Gilst W.H., Crijns H.J., et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc Res 54 (2002) 380-389
26. 2+ mobilization on release and activation of matrix metalloproteinases in hepatocellular carcinoma cells. Zhonghua Zhong Liu Za Zhi 26 (2004) 525-527
27. Ohashi N., Mitamura H., Tanimoto K., Fukuda Y., Kinebuchi O., Kurita Y., et al. A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J Cardiovasc Pharmacol 44 (2004) 386-392
28. Kinebuchi O., Mitamura H., Shiroshita-Takeshita A., Kurita Y., Ieda M., Ohashi N., et al. Oral verapamil attenuates the progression of pacing-induced electrical and mechanical remodeling of the atrium. Circ J 68 (2004) 494-500
29. Zaman A.G., Kearney M.T., Schecter C., Worthley S.G., and Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. Am Heart J 147 (2004) 823-827
30. Li H., Simon H., Bocan T.M., and Peterson J.T. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 46 (2000) 298-306